We found 3 drugmaker programs for Thyroid Eye Disease medicines and 3 charity funds (1 open at our last check). Tell us your insurance below and we'll show what to try first.
Help for Thyroid Eye Disease depends mostly on how you're covered. Pick the one that sounds like you. We'll name the funds and programs that fit, and what won't work, so you don't waste a phone call.
Independent foundations pay copays, coinsurance and sometimes insurance premiums for people who already have coverage. Funds open and close as donations come in, so each one shows what the foundation said on the date we checked.
Covers: Copays, coinsurance, deductibles and other health-related expenses.
Covers: Copays for FDA-approved medications (plus travel for some funds).
Covers: Out-of-pocket costs for approved medications. Up to $9,000 a year.
Copay cards lower what people with private insurance pay. Federal rules bar them for Medicare, Medicaid and TRICARE. Free medicine programs are for people without enough coverage and usually have income limits. We read each program on the drugmaker's own site.
Genentech co-pay program for commercially insured patients taking Enspryng for an FDA-approved use; eligibility criteria and benefit limits apply. Not valid under federal or state programs.
Genentech Patient Foundation gives free Genentech medicine to people without insurance coverage or with financial concerns who meet income requirements. Call 888-941-3331.
Genentech Access Solutions handles benefits checks, prior authorization help and referrals to independent co-pay foundations for patients with government insurance.
Enspryng is now approved for NMOSD and, since October 2026, thyroid eye disease. Genentech's October 16, 2026 approval announcement directs people prescribed Enspryng to Genentech Access Solutions at (866) 422-2377.
Eligible commercially insured patients may pay as little as $0 for Lumvoa medication and infusion expenses. Patients must be enrolled in ViridianCares and meet all eligibility requirements; people with government insurance are not eligible for copay assistance.
After the doctor enrolls a patient, ViridianCares assigns a dedicated Patient Access Liaison who helps with insurance coverage, reviews all financial support options and helps keep treatment on schedule. Call 1-866-VCARES1 (1-866-822-7371), Monday to Friday, 8 AM to 8 PM ET.
Phone is 1-866-VCARES1. Viridian's June 26, 2026 approval release describes ViridianCares as offering patient access liaisons, insurance coverage support, benefit verification and financial assistance for eligible patients. No free-drug or patient assistance program for uninsured patients is described on the pages read. Copay terms PDF: https://www.lumvoa.com/content/lumvoa-copay-terms-and-conditions.pdf (not read).
Amgen Commercial Co-Pay Program: eligible commercially insured patients may pay as little as $0 per dose of TEPEZZA.
Same program may cover infusion costs, as little as $0. Massachusetts and Rhode Island residents cannot get infusion (administration) help.
Amgen By Your Side: a Patient Access Liaison reviews your insurance coverage criteria, estimates your potential out-of-pocket costs, explains whether your doctor needs to get prior authorization, helps with required labs, and helps coordinate appointments, find infusion centers and manage your infusion schedule. Enrolling is free.
Copay program excludes any prescription paid in part or in full by government programs (Medicare, Medicaid, VA, DOD, TRICARE) and any state or foundation program. Offer cannot be combined with rebates, coupons or similar offers. For government-insured or uninsured patients, Amgen's page lists only independent organizations (Patient Advocate Foundation, The Assistance Fund, NORD), which have their own eligibility rules and are not endorsed by Amgen. 1-833-483-7399 is the TEPEZZA Nurse Advocate line for thyroid eye disease questions, not the support program.
Most of these programs start with one call, and having these ready makes it shorter. Tick them off as you go. Nothing here is saved or sent anywhere.
Call the drugmaker's support line first. Its case managers check your benefits and often fill out forms with your doctor. If a charity fund is closed, sign up on the foundation's page to hear when it reopens. Most programs need renewing every year, and many copay cards reset in January.
Yes. Trial Friend lists 3 drugmaker programs for Thyroid Eye Disease medicines and 3 charity funds, 1 of them open at our last check. We checked every one at the source on or before October 19, 2026. Which ones fit depends on your insurance. Copay cards are for people with private insurance, charity funds usually need some insurance, and free medicine programs are for people without enough coverage.
No. Federal rules bar drugmaker copay cards for drugs paid by Medicare, Medicaid or TRICARE. For Thyroid Eye Disease, 0 charity funds on this page accept Medicare, and 1 drugmaker free medicine program names Medicare patients among those who may qualify. In 2026, Medicare Part D also caps yearly out-of-pocket costs for covered drugs at $2,100.
At our last check, The Assistance Fund's Thyroid Eye Disease (TED) fund was open to new applicants. Funds open and close as donations come in, so check the foundation's page before you apply.
Of the drugmaker programs for Thyroid Eye Disease medicines, 1 offers free medicine to people without insurance who qualify, usually with income limits. Most charity funds pay copays and premiums, so they need some insurance. The drugmaker's support line can also check whether you qualify for coverage you don't have yet.
How we check: drugmaker programs come only from each drugmaker's own pages. Fund status is copied from each foundation's list (The Assistance Fund, Good Days, TotalAssist) on the date shown. Programs change, so confirm with the program before you rely on it. Trial Friend shares information, not financial, legal or medical advice, and each program decides who qualifies. See something wrong? Email jason@trialfriend.com.
